Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. Our goal is to bring life-changing therapies to patients worldwide who are living with serious autoantibody-driven conditions. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology.
We are advancing Telitacicept, a novel, dual-target recombinant fusion protein that inhibits both BLyS (BAFF) and APRILβtwo key cytokines involved in B cell survival and autoantibody production. In a Phase 3 clinical trial in generalized myasthenia gravis in China, Telitacicept demonstrated a 4.8-point improvement in MG-ADL (Myasthenia Gravis Activities of Daily Living scale) vs. placebo at 24 weeks, the primary endpoint of the trial.
Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase 3 clinical trial in gMG is currently underway across the United States, Europe, and South America to support potential approval in the United States and Europe.
We are looking for motivated Medical Directors/Sr. Medical Directors to join our growing global clinical development team.
By becoming a team member here at Vor, youβll have access to competitive health, dental, and vision coverage, as well as life insurance, and short term and long-term disability insurance. We value work life balance, you'll benefit from discretionary time off, parental leave, and an excellent 401(k) package. We are conveniently located in Boston with easy access to public transportation and ample parking.
As an equal opportunity employer, we at Vor Bio know that diversity inspires innovation, inclusiveness, and creativity. We invite you to come as you are. All applicants will be considered for employment agnostic to race, age, color, religion, sex, sexual orientation, gender identity, national origin, veteran or disability status.
Please visit our website at https://www.vorbio.com/ for more information.